A Phase I, Double-Blind, Double-Dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-State and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-State on the QT/QTc Interval, in 2 Randomized Panels of Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 04 Mar 2010
At a glance
- Drugs Efavirenz; Moxifloxacin; Rilpivirine
- Indications Bacterial infections; HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen R&D Ireland
- 08 Dec 2009 Results will be presented at the 12th European AIDS Conference.
- 18 Apr 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.